Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Net Income towards Common Stockholders: 2022-2025

Historic Net Income towards Common Stockholders for ARS Pharmaceuticals (SPRY) over the last 4 years, with Sep 2025 value amounting to -$53.2 million.

  • ARS Pharmaceuticals' Net Income towards Common Stockholders fell 144.58% to -$53.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.8 million, marking a year-over-year decrease of 50.04%. This contributed to the annual value of $8.0 million for FY2024, which is 114.71% up from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Net Income towards Common Stockholders of -$53.2 million as of Q3 2025, which was down 11.72% from -$47.6 million recorded in Q2 2025.
  • ARS Pharmaceuticals' Net Income towards Common Stockholders' 5-year high stood at $47.2 million during Q4 2024, with a 5-year trough of -$53.2 million in Q3 2025.
  • For the 3-year period, ARS Pharmaceuticals' Net Income towards Common Stockholders averaged around -$19.0 million, with its median value being -$18.7 million (2023).
  • Per our database at Business Quant, ARS Pharmaceuticals' Net Income towards Common Stockholders slumped by 224.76% in 2023 and then spiked by 561.54% in 2024.
  • Over the past 4 years, ARS Pharmaceuticals' Net Income towards Common Stockholders (Quarterly) stood at -$15.4 million in 2022, then soared by 33.78% to -$10.2 million in 2023, then skyrocketed by 561.54% to $47.2 million in 2024, then tumbled by 144.58% to -$53.2 million in 2025.
  • Its Net Income towards Common Stockholders was -$53.2 million in Q3 2025, compared to -$47.6 million in Q2 2025 and -$37.2 million in Q1 2025.